Oncternal Therapeutics (ONCT) 10-Q2009 Q3 Quarterly report

Filed: 9 Nov 09, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: abroad, addressing, allocated, ASU, Chilcott, deposit, detrimental, director, dutasteride, entirety, Eventsin, FASB, fixed, ghrelin, guidance, intent, introduction, Letter, liquidated, maturity, mechanism, original, persuasive, Pfizer, post, request, requested, requesting, retroactively, Topic, troponin, uncertainty, underSubsequent, Warner

Removed: accepting, add, antigen, asset, began, binding, Bulletin, ceased, collapse, criteria, EITF, elevated, extension, Gamble, intervention, LLC, manager, NAV, noncompetition, orderly, outlined, principal, Procter, SAB, satisfied, Savient, shipped, summer, unrealized, Wyeth

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ONCT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 12.1

GTx, Inc.
Computation of Deficiency of Earnings Available to Cover Fixed Charges


	Nine Months Ended			Year Ended December 31,
	September 30, 2009			2008			2007			2006			2005			2004
Loss:
Pretax loss from continuing operations	$	(35,381	)	$	(51,780	)	$	(40,359	)	$	(35,510	)	$	(36,839	)	$	(22,348	)
Fixed charges (from below)		77			89			35			32			32			21


Total loss	$	(35,304	)	$	(51,691	)	$	(40,324	)	$	(35,478	)	$	(36,807	)	$	(22,327	)


Fixed charges:
Estimated interest portion of rent expenses	$	77		$	89		$	35		$	32		$	32		$	21


Total fixed charges	$	77		$	89		$	35		$	32		$	32		$	21


Coverage deficiency	$	(35,381	)	$	(51,780	)	$	(40,359	)	$	(35,510	)	$	(36,839	)	$	(22,348	)